Condom, MariaMussetti, AlbertoMaluquer, ClaraParody, RocíoGonzález Barca, EvaArnan, MontserratAlbasanz Puig, AdaiaPomares, HelenaSalas, Maria QueraltCarro, ItziarPeña, MartaClapes, VictòriaBaca Cano, CristinaOliveira Ramos, Ana CarlaSanz Linares, GabrielaMoreno González, GabrielMercadal, SantiagoBoqué Genovard, ConcepciónGudiol González, CarlotaDomingo Domènech, EvaSureda, Anna2021-04-072021-04-072021-03-03https://hdl.handle.net/2445/176037Background: Clinical outcomes of novel coronavirus 2019 disease (COVID-19) in onco-hematological patients are unknown. When compared to non-immunocompromised patients, onco-hematological patients seem to have higher mortality rates. Aims: We describe the characteristics and outcomes of a consecutive cohort of 24 onco-hematological patients with COVID-19 during the first month of the pandemic. We also describe variations in healthcare resource utilization within our hematology department. Methods and results: Data from patients between the first month of the pandemic were retrospectively collected. Clinical and logistic data were also collected and compared with the average values from the prior 3 months of activity. Prevalence of COVID-19 in our hematological population was 0.4%. Baseline characteristics were as follows: male sex: 83%, lymphoid diseases: 46%, median age: 69 (22-82) years. Median follow-up in survivors was 14 (9-28) days and inpatient mortality rate was 46%. Average time to moderate/severe respiratory insufficiency and death were 3 (1-10) and 10 (3-18) days, respectively. Only 1 out of every 12 patients who developed moderate to severe respiratory insufficiency recovered. Upon univariate analysis, the following factors were associated with higher mortality: age ≥ 70 years (P = .01) and D-dimer ≥900 mcg/L (P = .04). With respect to indirect effects during the COVID-19 pandemic, and when compared with the prior 3 months of activity, inpatient mortality (excluding patients with COVID-19 included in the study) increased by 56%. This was associated with a more frequent use of vasoactive drugs (+300%) and advanced respiratory support (+133%) in the hematology ward. In the outpatient setting, there was a reduction in initial visits (-55%) and chemotherapy sessions (-19%). A significant increase in phone visits was reported (+581%). Conclusion: COVID-19 pandemic is associated with elevated mortality in hematological patients. Negative indirect effects are also evident within this setting.10 p.application/pdfengcc by (c) Condom et al., 2021http://creativecommons.org/licenses/by/3.0/es/COVID-19OncologiaMalalties hematològiquesCOVID-19OncologyHematologic diseasesinfo:eu-repo/semantics/article2021-03-25info:eu-repo/semantics/openAccess33656801